Accelerating the Advancement of Universal CAR-NK Cell Therapy
Founded in 2014, iMBioRay is engaged in the treatment of tumors and immune diseases. In 2016, it focused on the development of innovative general-purpose off-the-shelf CAR-NK cell therapy. Through its original technology platform, it has developed a series of cell and antibody drugs, committed to In order to solve unmet clinical diseases, multiple product pipelines are being pushed to the clinic simultaneously.
This round of financing will be used to advance the development of Embraer’s unique non-genetically modified CAR-raNK and tiNK cell therapies, and to advance the company’s leading off-the-shelf CAR-raNK cell therapy candidates, IBR733 and IBR854, to the clinical stage, accelerating the company’s IND-enabling studies of multiple tiNK and NK Cell Engager cell therapy candidates, as well as new GMP plant construction, talent echelon construction, strengthening external business cooperation and replenishing working capital.
One-stop preclinical service platform for Medicilon cellular immunotherapy drugs.
High all-round support for CAR-NK preclinical development.
CAR-NK adoptive cell therapy is to modify NK cells with CAR gene to give NK cells the ability to target and recognize tumor cells. After in vitro expansion, they are injected into the human body to achieve the effect of tumor treatment. Compared with CAR-T cells, CAR-NK has a wide range of sources, is more suitable for in vitro culture and genetic modification, and has the potential to be applied to allogeneic cells; solid tumors are sensitive to antigen-dependent NK cells, and CAR-NK is effective in solid tumors. Advantages; in addition, the CAR-NK production process is simpler, which is expected to greatly shorten the treatment cycle and price.
At the same time, the general off-the-shelf CAR-NK therapy meets the industry needs and trends to improve cell manufacturing efficiency and reduce costs. We have reason to believe that the prospect and market space of CAR-NK therapy will be unlimited.
Driven by the development of the industry, Medicilon has established a one-stop preclinical research and development platform for cellular immunotherapy drugs in order to meet customer requirements, which can undertake a variety of immunotherapy methods including CAR-NK, including but not limited to CAR- T, TCR-T, CAR-NK, TIL, etc., including in vitro/in vivo pharmacodynamic studies, pharmacokinetics studies, safety evaluation, etc., and have completed the preclinical development of multiple tumor immunotherapy programs for customers project.